Miniatura

Fitxers

ijc.31536.pdf (1.03 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2018-04-18

Llicència de publicació

cc by (c) Vermeulen et al., 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/122197

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1002/ijc.31536

Resum

Recent prospective studies have shown that dysregulation of the immune system may precede the development of B‐cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case–control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years before diagnosis (range 2.01–15.97) in 268 incident cases of BCL (including multiple myeloma [MM]) and matched controls. Linear mixed models and partial least square analyses were used to analyze the association between levels of immune marker and the incidence of BCL and its main histological subtypes and to investigate potential biomarkers predictive of the time to diagnosis. Linear mixed model analyses identified associations linking lower levels of fibroblast growth factor‐2 (FGF‐2 p = 7.2 × 10−4) and transforming growth factor alpha (TGF‐α, p = 6.5 × 10−5) and BCL incidence. Analyses stratified by histological subtypes identified inverse associations for MM subtype including FGF‐2 (p = 7.8 × 10−7), TGF‐α (p = 4.08 × 10−5), fractalkine (p = 1.12 × 10−3), monocyte chemotactic protein‐3 (p = 1.36 × 10−4), macrophage inflammatory protein 1‐alpha (p = 4.6 × 10−4) and vascular endothelial growth factor (p = 4.23 × 10−5). Our results also provided marginal support for already reported associations between chemokines and diffuse large BCL (DLBCL) and cytokines and chronic lymphocytic leukemia (CLL). Case‐only analyses showed that Granulocyte‐macrophage colony stimulating factor levels were consistently higher closer to diagnosis, which provides further evidence of its role in tumor progression. In conclusion, our study suggests a role of growth‐factors in the incidence of MM and of chemokine and cytokine regulation in DLBCL and CLL.

Matèries

Limfomes, Citoquines

Matèries (anglès)

Lymphomas, Cytokines

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

VERMEULEN, Roel c. h., SABERI HOSNIJEH, Fatemeh, BODINIER, Barbara, PORTENGEN, Lützen, LIQUET, Benoît, GARRIDO MANRIQUEZ, Javiera, LOKHORST, Henk, BERGDAHL, Ingvar a., KYRTOPOULOS, Soterios, JOHANSSON, Ann-sofie, GEORGIADIS, Panagiotis, MELIN, Beatrice s., PALLI, Domenico, KROGH, Vittorio, PANICO, Salvatore, SACERDOTE, Carlotta, TUMINO, Rosario, VINEIS, Paolo, CASTAGNÉ, Raphaele, CHADEAU-HYAM, Marc, EnviroGenoMarkers Consortium, BOTSIVALI, Maria, CHATZIIOANNOU, Aristotelis, VALAVANIS, Ioannis, KLEINJANS, Jos c. s., KOK, Theo m. c. m. de, KEUN, Hector c., ATHERSUCH, Toby j., KELLY, Rachel s., LENNER, Per, HALLMANS, Göran, STEPHANOU, Euripides g., MYRIDAKIS, Antonis, KOGEVINAS, Manolis, FAZZO, Lucia, SANTIS, Marco de, COMBA, Pietro, BENDINELLI, Benedetta, KIVIRANTA, Hannu, RANTAKOKKO, Panu, AIRAKSINEN, Riikka, RUOKOJARVI, Paivi, GILTHORPE, Mark, FLEMING, Sarah, FLEMING, Thomas, TU, Yu-kang, LUNDH, Thomas, CHIEN, Kuo-liong, CHEN, Wei j., LEE, Wen-chung, KATE HSIAO, Chuhsing, KUO, Po-hsiu, HUNG, Hung, LIAO, Shu-fen. Pre-diagnostic blood immune markers, incidence and progression
                of B-cell lymphoma and multiple myeloma: Univariate and
                functionally informed multivariate analyses. _International Journal of Cancer_. 2018. [consulta: 20 de gener de 2026]. ISSN: 1097-0215. [Disponible a: https://hdl.handle.net/2445/122197]

Exportar metadades

JSON - METS

Compartir registre